Drug interactions
Eprosartan-hydrochlorothiazide + Methoxsalen
Severity: Moderate
Eprosartan-hydrochlorothiazide and Methoxsalen: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Hydrochlorothiazide is a recognised photosensitizer and methoxsalen is used to deliberately induce photosensitivity in PUVA therapy. Together they may increase the risk of exaggerated phototoxic reactions such as severe sunburn or blistering.
What this interaction means in plain words
Eprosartan-hydrochlorothiazide and Methoxsalen can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Eprosartan-hydrochlorothiazide belongs to Cardiovascular; Methoxsalen belongs to Anti Fungals.
Why it happens
Additive photosensitizing effects of the two drugs on skin exposed to ultraviolet radiation.
What to do
Counsel the patient on strict sun protection and eye protection, and consider reducing the UVA dose or timing for PUVA sessions. Examine the skin for erythema after early treatments, or consider an alternative antihypertensive if reactions occur.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Eprosartan-hydrochlorothiazide and Methoxsalen, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Eprosartan-hydrochlorothiazide
- Aliskiren + Eprosartan-hydrochlorothiazide Contraindicated
- Dofetilide + Eprosartan-hydrochlorothiazide Contraindicated
- Eprosartan-hydrochlorothiazide + Sparsentan Contraindicated
- Aceclofenac + Eprosartan-hydrochlorothiazide Major
- Aldesleukin + Eprosartan-hydrochlorothiazide Major
- Amifostine + Eprosartan-hydrochlorothiazide Major
Other interactions of Methoxsalen
- Fezolinetant + Methoxsalen Contraindicated
- Demeclocycline + Methoxsalen Major
- Fedratinib + Methoxsalen Major
- Methoxsalen + Pirfenidone Major
- Methoxsalen + Tasimelteon Major
- Adapalene + Methoxsalen Moderate
Frequently asked questions
Can I take Eprosartan-hydrochlorothiazide with Methoxsalen?
MediHelp rates the interaction as moderate. Eprosartan-hydrochlorothiazide and Methoxsalen can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Hydrochlorothiazide is a recognised photosensitizer and methoxsalen is used to deliberately induce photosensitivity in PUVA therapy. Together they may increase the risk of exaggerated phototoxic reactions such as severe sunburn or blistering.
How serious is the interaction between Eprosartan-hydrochlorothiazide and Methoxsalen?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Counsel the patient on strict sun protection and eye protection, and consider reducing the UVA dose or timing for PUVA sessions. Examine the skin for erythema after early treatments, or consider an alternative antihypertensive if reactions occur.
What other medicines interact with Eprosartan-hydrochlorothiazide?
MediHelp also lists interactions of Eprosartan-hydrochlorothiazide with, for example, Aliskiren, Dofetilide, Sparsentan. The full list is on the Eprosartan-hydrochlorothiazide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
